secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001680367-23-000049
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs Q2 net loss $21.3M ($0.50/sh); cash $117.2M; SL-172154 trials advancing
--------------------------------------------------------------------------------

- Cash and investments $117.2M at June 30, 2023, down from $214.2M a year earlier; runway through end of 2024.
- Net loss of $21.3M ($0.50 per share) for Q2 2023 vs. $27.4M ($0.65) in Q2 2022; R&D spend decreased to $18.2M.
- Phase 1A PROC monotherapy data presented at ASCO 2023; 3 mg/kg dose selected for combination cohorts.
- Enrollment completed in dose-escalation part of Phase 1A/B for SL-172154 in AML/HR-MDS; initial combo data expected Q4 2023.
- GADLEN platform: second NHP toxicology study showed inferior B-cell depletion; no IND planned until resolved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000168036723000049/0001680367-23-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000168036723000049/sttk-20230810.htm
  HTML page:      https://secwatch.observer/filing/0001680367-23-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer